| abstract |
FIELD: medicine, pharmaceutics. n SUBSTANCE: claimed invention relates to the field of biotechnology and discloses a group of humanised recombinant antibodies, which specifically bind with human CDCP1. The claimed invention also discloses a nucleic acid, which codes an antibody, an expression vector, which contains the claimed nucleic acid and a prokaryotic or eukaryotic host cell, intended for obtaining the claimed antibodies. The method of obtaining the claimed antibodies with the application of the claimed host cell is described. A pharmaceutical composition for cancer treatment, characterised by the super-expression of CDCP1, is obtained by the application of the said antibody as the active one. n EFFECT: claimed invention makes it possible to obtain the humanised antibodies with improved CDCP1 binding properties. n 20 cl, 5 dwg, 4 tbl, 6 ex |